Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients

被引:0
|
作者
Hui Zhou
Yan Gao
Xiao-Liang Cheng
Zhong-Dong Li
机构
[1] General Hospital of Air Force,Department of Clinical Pharmacy
[2] PLA,Department of Pharmaceutics, School of Pharmaceutical Sciences
[3] Peking University,undefined
关键词
Cyclosporine A; Allogeneic hematopoietic stem cell transplantation; Population pharmacokinetics; NONMEM;
D O I
暂无
中图分类号
学科分类号
摘要
To set up a population pharmacokinetic (PPK) model of cyclosporine A (CsA) in Chinese allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients to provide reference for individualized medication in clinical practice. 281 trough plasma concentrations of CsA and covariates such as demographics, clinical laboratory values and coadministration were retrospectively collected from 73 allo-HSCT patients. Population modeling was performed using general model of NONMEM expressed by differential equation. Hematocrit (HCT), plasma albumin (ALB) level, and coadministration of itraconazole (ITR) were found to significantly affect the clearance of CsA (CL, L/h). The final model formula was: CL = 28.2 × [1 − 0.0263 × (HCT − 26.62)] × [1 − 0.0289 × (ALB − 37.63)] × [1 − 0.146 × ITR] (L/h); V = 1,080 (L); Ka = 1.28 (h−1); F = 0.711. The interindividual variabilities for CL, V and F were 21.4, 41.5 and 6.07 %, respectively. The residual error was 0.00422 mg/L. The PPK model was validated to be effective and stable by bootstrap method. Clinical applications showed there was a good linear correlation between the predicted concentrations and the observed (y = 1.0095x + 0.0082, r = 0.9309, p < 0.0001). The PPK final model of CsA in Chinese allo-HSCT patients can be established using the NONMEM program which can be applied in clinical allo-HSCT practice when characteristics of patients fit in with those of subpopulation in the study.
引用
收藏
页码:271 / 278
页数:7
相关论文
共 50 条
  • [31] Sinus bradycardia associated with cyclosporine following allogeneic hematopoietic stem cell transplantation
    G Fujisaki
    M Kami
    N Murashige
    Y Kishi
    C Inokuchi
    R Tanosaki
    S Momomura
    Bone Marrow Transplantation, 2005, 35 : 211 - 212
  • [32] Sinus bradycardia associated with cyclosporine following allogeneic hematopoietic stem cell transplantation
    Fujisaki, G
    Kami, M
    Murashige, N
    Kishi, Y
    Inokuchi, C
    Tanosaki, R
    Momomura, S
    BONE MARROW TRANSPLANTATION, 2005, 35 (02) : 211 - 212
  • [33] Risk analyses of EBV reactivation after allogeneic hematopoietic stem cell transplantation in Chinese population
    Ru, Yuhua
    Zhu, Ziling
    Xu, Yang
    Chen, Suning
    Tang, Xiaowen
    Han, Yue
    Qiu, Huiying
    Fu, Chengcheng
    Chen, Jia
    Wu, Depei
    BONE MARROW TRANSPLANTATION, 2019, 54 : 415 - 416
  • [34] Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients
    Selby, Philip R. R.
    Heffernan, Aaron J. J.
    Yeung, David
    Warner, Morgyn S. S.
    Peake, Sandra L. L.
    Hahn, Uwe
    Wallis, Steven C. C.
    Mcwhinney, Brett
    Ungerer, Jacobus P. J.
    Shakib, Sepehr
    Roberts, Jason A. A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (03)
  • [35] Topical Cyclosporine Pretreatment of Ocular Surface in Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Chun, Yoon Hong
    Beak, Jin Uk
    Kim, Hyun-Seung
    Na, Kyung-Sun
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (09) : 628 - 632
  • [36] Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients
    Prohn, Marita
    Viberg, Anders
    Zhang, Da
    Dykstra, Kevin
    Davis, Casey
    Macha, Sreeraj
    Sabato, Philip
    de Alwis, Dinesh
    Iwamoto, Marian
    Fancourt, Craig
    Cho, Carolyn R.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (03): : 255 - 267
  • [37] Population pharmacokinetics of cyclosporine in Chinese cardiac transplant recipients
    Yin, OQP
    Lau, SK
    Chow, MSS
    PHARMACOTHERAPY, 2006, 26 (06): : 790 - 797
  • [38] Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review
    Pession, Andrea
    Zama, Daniele
    Muratore, Edoardo
    Leardini, Davide
    Gori, Davide
    Guaraldi, Federica
    Prete, Arcangelo
    Turroni, Silvia
    Brigidi, Patrizia
    Masetti, Riccardo
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (02): : 1 - 14
  • [39] Pharmacokinetics of Cyclosporine a Conversion From Twice-Daily Infusion to Oral Administration in Allogeneic Hematopoietic Stem Cell Transplantation
    Inoue, Yasuyuki
    Saito, Tasuku
    Ogawa, Kohei
    Nishio, Yuji
    Kosugi, Shigeki
    Suzuki, Yoshinori
    Kato, Masayuki
    Sakai, Hirotaka
    Takahashi, Masatomo
    Miura, Ikuo
    AMERICAN JOURNAL OF THERAPEUTICS, 2014, 21 (05) : 377 - 384
  • [40] Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation
    Wu, Xuemei
    Xie, Helin
    Lin, Weiwei
    Yang, Ting
    Li, Nainong
    Lin, Shanshan
    Yuan, Xiaohong
    Ren, Jinhua
    Li, Xiaofan
    Huang, Xian
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (05): : 529 - 538